Gls-012
Advanced Non-Small Cell Lung Cancer
Guangzhou Gloria Biosciences Co., Ltd.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
11 Active assets in the Advanced Non-Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
pf-08634404 Pfizer | Phase 3 | BB |
Ssgj-707 Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 3 | B |
Bortezomib Millennium Pharmaceuticals, Inc. | Phase 2 | B |
bnt116 Regeneron Pharmaceuticals | Phase 2 | B |
ibi351 Guangdong Association of Clinical Trials | Phase 2 | B |
View all 15 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →